BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys. 2013;87:22-32. [PMID: 23219567 DOI: 10.1016/j.ijrobp.2012.08.043] [Cited by in Crossref: 115] [Cited by in F6Publishing: 86] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Bowen SR, Saini J, Chapman TR, Miyaoka RS, Kinahan PE, Sandison GA, Wong T, Vesselle HJ, Nyflot MJ, Apisarnthanarax S. Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients. Radiother Oncol. 2015;115:203-210. [PMID: 25934165 DOI: 10.1016/j.radonc.2015.04.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
2 Wei Y, Dai F, Zhao T, Tao C, Wang L, Ye W, Zhao W. Transcatheter arterial chemoembolization monotherapy vs combined transcatheter arterial chemoembolization-percutaneous microwave coagulation therapy for massive hepatocellular carcinoma (≥10 cm). Cancer Manag Res 2018;10:5273-82. [PMID: 30464624 DOI: 10.2147/CMAR.S172395] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Koirala N, Das D, Fayazzadeh E, Sen S, McClain A, Puskas JE, Drazba JA, McLennan G. Folic acid conjugated polymeric drug delivery vehicle for targeted cancer detection in hepatocellular carcinoma. J Biomed Mater Res A 2019;107:2522-35. [PMID: 31334591 DOI: 10.1002/jbm.a.36758] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
4 Okazaki E, Yamamoto A, Nishida N, Hamuro M, Ogino R, Hosono M, Shimatani Y, Tsutsumi S, Hamamoto S, Sohgawa E, Jogo A, Miki Y. Three-dimensional conformal radiotherapy for locally advanced hepatocellular carcinoma with portal vein tumour thrombosis: evaluating effectiveness of the model for end-stage liver disease (MELD) score compared with the Child-Pugh classification. Br J Radiol 2016;89:20150945. [PMID: 27164029 DOI: 10.1259/bjr.20150945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
5 Kim KH, Kim MS, Chang JS, Han KH, Kim do Y, Seong J. Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma. Liver Int. 2014;34:784-794. [PMID: 24330457 DOI: 10.1111/liv.12436] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
6 Wu L, Pang Y, Qin G, Xi G, Wu S, Wang X, Chen T. Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives. PLoS One 2017;12:e0171840. [PMID: 28182780 DOI: 10.1371/journal.pone.0171840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Abdel-Rahman O, Elsayed Z. External beam radiotherapy for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2017;3:CD011314. [PMID: 28267205 DOI: 10.1002/14651858.CD011314.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Wo JY, Dawson LA, Zhu AX, Hong TS. An emerging role for radiation therapy in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2014;23:353-368. [PMID: 24560114 DOI: 10.1016/j.soc.2013.10.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
9 Aitken KL, Hawkins MA. Stereotactic body radiotherapy for liver metastases. Clin Oncol (R Coll Radiol). 2015;27:307-315. [PMID: 25682933 DOI: 10.1016/j.clon.2015.01.032] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
10 Wu B, Yuan Y, Liu J, Shang H, Dong J, Liang X, Wang D, Chen Y, Wang C, Zhou Y, Jing H, Cheng W. Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma. J Nanobiotechnology 2021;19:177. [PMID: 34118951 DOI: 10.1186/s12951-021-00923-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Tchelebi L, Zaorsky N, Mackley H. Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. Biomedicines 2018;6:E7. [PMID: 29301352 DOI: 10.3390/biomedicines6010007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol. 2013;19:7316-7326. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
13 Zhang Z, Zhang E, Zhang B, Chen X, Zhang W. Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: A comprehensive review. WJGS 2021;13:796-805. [DOI: 10.4240/wjgs.v13.i8.796] [Reference Citation Analysis]
14 Jacob J, Nguyen F, Deutsch E, Mornex F. [Stereotactic body radiation therapy in the management of liver tumours]. Cancer Radiother 2014;18:486-94. [PMID: 25195113 DOI: 10.1016/j.canrad.2014.07.145] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Yoon K, Kwak J, Cho B, Park JH, Yoon SM, Lee SW, Kim JH. Gated Volumetric-Modulated Arc Therapy vs. Tumor-Tracking CyberKnife Radiotherapy as Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Dosimetric Comparison Study Focused on the Impact of Respiratory Motion Managements. PLoS One 2016;11:e0166927. [PMID: 27875568 DOI: 10.1371/journal.pone.0166927] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
16 Kamimura K, Suda T, Yokoo T, Kamimura H, Kanefuji T, Tsuchiya A, Takamura M, Kawai H, Waguri N, Yamagiwa S. Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial. BMC Cancer. 2017;17:322. [PMID: 28490356 DOI: 10.1186/s12885-017-3320-7.] [Reference Citation Analysis]
17 Kamimura K, Suda T, Yokoo T, Kamimura H, Kanefuji T, Tsuchiya A, Takamura M, Kawai H, Waguri N, Yamagiwa S, Terai S. Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial. BMC Cancer 2017;17:322. [PMID: 28490356 DOI: 10.1186/s12885-017-3320-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Yu JI, Cho J, Park HC, Lim DH, Gwak G, Paik SW. Child-Pugh Score Maintenance in Cirrhotic Hepatocellular Carcinoma Patients after Radiotherapy: Aspects of Gastroduodenal Complications. Tumori Journal 2018;100:645-51. [DOI: 10.1177/1778.19270] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
19 Brasse D, Burckel H, Marchand P, Rousseau M, Ouadi A, Vanstalle M, Finck C, Laquerriere P, Boisson F. Comparison of the [18F]-FDG and [18F]-FLT PET Tracers in the Evaluation of the Preclinical Proton Therapy Response in Hepatocellular Carcinoma. Mol Imaging Biol 2021;23:724-32. [PMID: 33847900 DOI: 10.1007/s11307-021-01602-3] [Reference Citation Analysis]
20 Rim CH, Koun S, Park HC, Lee S, Kim CY. Radioprotective effects of mistletoe extract in zebrafish embryos in vivo. Int J Radiat Biol 2019;95:1150-9. [PMID: 30836032 DOI: 10.1080/09553002.2019.1590661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chen XH, Li ZQ, Peng H, Jin SM, Fu HQ, Zhu TC, Weng XG. Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer. Onco Targets Ther 2013;6:527-30. [PMID: 23700371 DOI: 10.2147/OTT.S44162] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Chapman TR, Bowen SR, Schaub SK, Yeung RH, Kwan SW, Park JO, Yu L, Harris WP, Johnson GE, Liou IW. Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: Defining clinically relevant endpoints. Pract Radiat Oncol. 2018;8:157-166. [PMID: 29426691 DOI: 10.1016/j.prro.2017.10.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
23 Qi WX, Fu S, Zhang Q, Guo XM. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol. 2015;114:289-295. [PMID: 25497556 DOI: 10.1016/j.radonc.2014.11.033] [Cited by in Crossref: 63] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
24 Kennedy AS. Radiation oncology approaches in liver malignancies. Am Soc Clin Oncol Educ Book 2014;:e150-5. [PMID: 24857096 DOI: 10.14694/EdBook_AM.2014.34.e150] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Hong TS, Grassberger C, Yeap BY, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler CE, Popescu I, DeLaney TF, Zhu AX, Duda DG. Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. NPJ Precis Oncol 2018;2:22. [PMID: 30374460 DOI: 10.1038/s41698-018-0065-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
26 Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY, Kim CM. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel). 2019;11. [PMID: 30781391 DOI: 10.3390/cancers11020230] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, Navarria P, Fogliata A, Tomatis S, D'Agostino G, Iftode C, Mancosu P, Ceriani R, Torzilli G. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015;141:1301-1309. [PMID: 25644863 DOI: 10.1007/s00432-015-1929-y] [Cited by in Crossref: 93] [Cited by in F6Publishing: 63] [Article Influence: 15.5] [Reference Citation Analysis]
28 Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol 2016;23:e605-14. [PMID: 28050151 DOI: 10.3747/co.23.3394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
29 Pollom EL, Lee K, Durkee BY, Grade M, Mokhtari DA, Wahl DR, Feng M, Kothary N, Koong AC, Owens DK, Goldhaber-Fiebert J, Chang DT. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. Radiology 2017;283:460-8. [PMID: 28045603 DOI: 10.1148/radiol.2016161509] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
30 Gach K, Grądzka I, Wasyk I, Męczyńska-Wielgosz S, Iwaneńko T, Szymański J, Koszuk J, Janecki T, Kruszewski M, Janecka A. Anticancer activity and radiosensitization effect of methyleneisoxazolidin-5-ones in hepatocellular carcinoma HepG2 cells. Chem Biol Interact 2016;248:68-73. [PMID: 26867810 DOI: 10.1016/j.cbi.2016.01.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
31 Ogawa K, Kamimura K, Watanabe Y, Motai Y, Kumaki D, Seki R, Sakamaki A, Abe S, Kawai H, Suda T, Yamagiwa S, Terai S. Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases. World J Clin Cases 2017;5:238-46. [PMID: 28685137 DOI: 10.12998/wjcc.v5.i6.238] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Huang CY, Tai WT, Wu SY, Shih CT, Chen MH, Tsai MH, Kuo CW, Shiau CW, Hung MH, Chen KF. Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling. Int J Radiat Oncol Biol Phys 2016;95:761-71. [PMID: 26960749 DOI: 10.1016/j.ijrobp.2016.01.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
33 Zhu J, Yin T, Xu Y, Lu XJ. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. J Cell Physiol. 2019;234:12122-12132. [PMID: 30644100 DOI: 10.1002/jcp.28048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
34 Huang Y, Chen SW, Fan CC, Ting LL, Kuo CC, Chiou JF. Clinical parameters for predicting radiation-induced liver disease after intrahepatic reirradiation for hepatocellular carcinoma. Radiat Oncol. 2016;11:89. [PMID: 27369241 DOI: 10.1186/s13014-016-0663-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
35 Fukuda K, Okumura T, Abei M, Fukumitsu N, Ishige K, Mizumoto M, Hasegawa N, Numajiri H, Ohnishi K, Ishikawa H. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci. 2017;108:497-503. [PMID: 28012214 DOI: 10.1111/cas.13145] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
36 Choi C, Lee GH, Son A, Yoo GS, Yu JI, Park HC. Downregulation of Mcl-1 by Panobinostat Potentiates Proton Beam Therapy in Hepatocellular Carcinoma Cells. Cells 2021;10:554. [PMID: 33806487 DOI: 10.3390/cells10030554] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, Kim SS, Lee WJ, Kim DY, Kim CM. Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlenther Onkol 2014;190:882-90. [PMID: 24638270 DOI: 10.1007/s00066-014-0643-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
38 Huang CY, Hung MH, Shih CT, Hsieh FS, Kuo CW, Tsai MH, Chang SS, Hsiao YJ, Chen LJ, Chao TI, Chen KF. Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation. J Pharmacol Exp Ther 2018;366:410-21. [PMID: 29914877 DOI: 10.1124/jpet.118.249102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
39 Kirichenko A, Gayou O, Parda D, Kudithipudi V, Tom K, Khan A, Abrams P, Szramowski M, Oliva J, Monga D. Stereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic liver tumors. HPB (Oxford). 2016;18:88-97. [PMID: 26776856 DOI: 10.1016/j.hpb.2015.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
40 Chettiar ST, Malek R, Annadanam A, Nugent KM, Kato Y, Wang H, Cades JA, Taparra K, Belcaid Z, Ballew M, Manmiller S, Proia D, Lim M, Anders RA, Herman JM, Tran PT. Ganetespib radiosensitization for liver cancer therapy. Cancer Biol Ther 2016;17:457-66. [PMID: 26980196 DOI: 10.1080/15384047.2016.1156258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
41 Hansen L, Rosenkranz SJ, Vaccaro GM, Chang MF. Patients With Hepatocellular Carcinoma Near the End of Life: A Longitudinal Qualitative Study of Their Illness Experiences. Cancer Nurs 2015;38:E19-27. [PMID: 25122134 DOI: 10.1097/NCC.0000000000000188] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
42 Choi C, Koom WS, Kim TH, Yoon SM, Kim JH, Lee HS, Nam TK, Seong J. A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2014;90:1051-1060. [PMID: 25303890 DOI: 10.1016/j.ijrobp.2014.08.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
43 Qiu H, Moravan MJ, Milano MT, Usuki KY, Katz AW. SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center. J Gastrointest Cancer 2018;49:463-9. [PMID: 28710606 DOI: 10.1007/s12029-017-9990-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
44 Kavanagh BD. Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes. J Clin Oncol 2014;32:2827-31. [PMID: 25113758 DOI: 10.1200/JCO.2014.56.7362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
45 Wang PM, Chung NN, Hsu WC, Chang FL, Jang CJ, Scorsetti M. Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve. Rep Pract Oncol Radiother 2015;20:417-24. [PMID: 26696781 DOI: 10.1016/j.rpor.2015.03.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
46 Cha H, Lee EJ, Seong J. Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy. World J Gastroenterol 2017;23:2077-85. [PMID: 28373775 DOI: 10.3748/wjg.v23.i11.2077] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
47 Fukumitsu N, Yamashita T, Mima M, Demizu Y, Suzuki T, Soejima T. Dose distribution effects of spot-scanning proton beam therapy equipped with a multi-leaf collimator for pediatric brain tumors. Oncol Lett 2021;22:635. [PMID: 34295382 DOI: 10.3892/ol.2021.12896] [Reference Citation Analysis]
48 Bibault JE, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraya H, Lacornerie T, Lartigau E, Mirabel X. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One. 2013;8:e77472. [PMID: 24147002 DOI: 10.1371/journal.pone.0077472] [Cited by in Crossref: 76] [Cited by in F6Publishing: 59] [Article Influence: 9.5] [Reference Citation Analysis]
49 Oechsner M, Odersky L, Berndt J, Combs SE, Wilkens JJ, Duma MN. Dosimetric impact of different CT datasets for stereotactic treatment planning using 3D conformal radiotherapy or volumetric modulated arc therapy. Radiat Oncol 2015;10:249. [PMID: 26626865 DOI: 10.1186/s13014-015-0557-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
50 Burak KW, Sherman M. Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol. 2015;29:178-184. [PMID: 25965437 DOI: 10.1155/2015/824263] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
51 Rim CH, Yim HJ, Park S, Seong J. Recent clinical applications of external beam radiotherapy for hepatocellular carcinoma according to guidelines, major trials and meta-analyses. J Med Imaging Radiat Oncol. 2019;63:812-821. [PMID: 31482683 DOI: 10.1111/1754-9485.12948] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
52 Jung SH, Yu JI, Park HC, Lim DH, Han Y. A feasibility study evaluating the relationship between dose and focal liver reaction in stereotactic ablative radiotherapy for liver cancer based on intensity change of Gd-EOB-DTPA-enhanced magnetic resonance images. Radiat Oncol J 2016;34:64-75. [PMID: 27104169 DOI: 10.3857/roj.2016.34.1.64] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
53 Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer 2014;3:405-16. [PMID: 26280002 DOI: 10.1159/000343861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
54 Yu JI, Park HC, Oh D, Noh JM, Jung SH, Kim HY, Shin SW, Cho SK, Sinn DH, Paik YH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial.Int J Hyperthermia. 2016;32:331-338. [PMID: 26915594 DOI: 10.3109/02656736.2016.1144895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
55 Yasuda S, Kato H, Imada H, Isozaki Y, Kasuya G, Makishima H, Tsuji H, Ebner DK, Yamada S, Kamada T, Tsujii H, Kato N, Miyazaki M; Working Group for Liver Tumor. Long-Term Results of High-Dose 2-Fraction Carbon Ion Radiation Therapy for Hepatocellular Carcinoma. Adv Radiat Oncol 2020;5:196-203. [PMID: 32280819 DOI: 10.1016/j.adro.2019.09.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
56 Wu W, He X, Andayani D, Yang L, Ye J, Li Y, Chen Y, Li L. Pattern of distant extrahepatic metastases in primary liver cancer: a SEER based study. J Cancer 2017;8:2312-8. [PMID: 28819435 DOI: 10.7150/jca.19056] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
57 Wang PM, Hsu WC, Chung NN, Chang FL, Jang CJ, Fogliata A, Scorsetti M, Cozzi L. Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients. Radiat Oncol 2014;9:18. [PMID: 24410988 DOI: 10.1186/1748-717X-9-18] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
58 Chu SS, Kuo YH, Liu WS, Wang SC, Ho CH, Chen YC, Yang CC, Wu HC. Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study. Sci Rep 2021;11:1614. [PMID: 33452421 DOI: 10.1038/s41598-021-81176-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
59 Baheti AD, Dunham GM, Ingraham CR, Moshiri M, Lall C, Park JO, Li D, Katz DS, Madoff DC, Bhargava P. Clinical implications for imaging of vascular invasion in hepatocellular carcinoma. Abdom Radiol 2016;41:1800-10. [DOI: 10.1007/s00261-016-0763-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
60 Mastrocostas K, Jang HJ, Fischer S, Dawson LA, Munoz-Schuffenegger P, Sapisochin G, Kim TK. Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls. Abdom Radiol (NY) 2019;44:1795-807. [PMID: 30710166 DOI: 10.1007/s00261-019-01901-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 14.0] [Reference Citation Analysis]
61 Oladeru OT, Miccio JA, Yang J, Xue Y, Ryu S, Stessin AM. Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol 2016;7:433-40. [PMID: 27284477 DOI: 10.21037/jgo.2015.10.04] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
62 Yoo GS, Yu JI, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol 2018;24:3090-100. [PMID: 30065555 DOI: 10.3748/wjg.v24.i28.3090] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
63 Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016;34:460-468. [PMID: 26668346 DOI: 10.1200/jco.2015.64.2710] [Cited by in Crossref: 209] [Cited by in F6Publishing: 87] [Article Influence: 34.8] [Reference Citation Analysis]
64 Bamodu OA, Chang HL, Ong JR, Lee WH, Yeh CT, Tsai JT. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma. Cells 2020;9:E746. [PMID: 32197467 DOI: 10.3390/cells9030746] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
65 Gao Y, Li Z, Hong Y, Li T, Hu X, Sun L, Chen Z, Chen Z, Luo Z, Wang X, Kong J, Li G, Wang H, Leo HL, Yu H, Xi L, Guo Q. Decellularized liver as a translucent ex vivo model for vascular embolization evaluation. Biomaterials 2020;240:119855. [DOI: 10.1016/j.biomaterials.2020.119855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
66 Aitken K, Hawkins M. The Role of Radiotherapy and Chemoradiation in the Management of Primary Liver Tumours. Clinical Oncology 2014;26:569-80. [DOI: 10.1016/j.clon.2014.05.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
67 Zhang Y, Li T, Xiao H, Ji W, Guo M, Zeng Z, Zhang J. A knowledge-based approach to automated planning for hepatocellular carcinoma. J Appl Clin Med Phys 2018;19:50-9. [PMID: 29139208 DOI: 10.1002/acm2.12219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
68 Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 2019;25:2416-29. [PMID: 31171886 DOI: 10.3748/wjg.v25.i20.2416] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 16.0] [Reference Citation Analysis]
69 Allison RR, Patel RM, Mclawhorn RA. Radiation oncology: physics advances that minimize morbidity. Future Oncology 2014;10:2329-44. [DOI: 10.2217/fon.14.176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
70 Michel R, Françoise I, Laure P, Anouchka M, Guillaume P, Sylvain K. Dose to organ at risk and dose prescription in liver SBRT. Rep Pract Oncol Radiother 2017;22:96-102. [PMID: 28490979 DOI: 10.1016/j.rpor.2017.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
71 Hung SP, Huang BS, Hsieh CE, Lee CH, Tsang NM, Chang JT, Chen JS, Chou WC, Tseng JH, Hong JH. Clinical Outcomes of Patients With Unresectable Cholangiocarcinoma Treated With Proton Beam Therapy. Am J Clin Oncol 2020;43:180-6. [PMID: 31764017 DOI: 10.1097/COC.0000000000000646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
72 Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep. 2014;16:373. [PMID: 24488546 DOI: 10.1007/s11912-013-0373-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
73 Shimizu S, Okumura T, Oshiro Y, Fukumitsu N, Fukuda K, Ishige K, Hasegawa N, Numajiri H, Murofushi K, Ohnishi K, Mizumoto M, Nonaka T, Ishikawa H, Sakurai H. Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy. Radiat Oncol 2019;14:241. [PMID: 31881895 DOI: 10.1186/s13014-019-1451-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
74 Klein J, Korol R, Lo SS, Chu W, Lock M, Dorth JA, Ellis RJ, Mayr NA, Huang Z, Chung HT. Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma. Future Oncol 2014;10:2227-41. [PMID: 25471036 DOI: 10.2217/fon.14.167] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
75 Choi JY, Yu JI, Park HC, David Kwon CH, Kim JM, Joh J, Choi G, Park JB, Kim SJ, Lee SH, Cho W, Lee KW, Na B, Oh DK, Lee N, Cho CW, Lee S, Lee S. The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus. Liver Transpl 2017;23:545-51. [DOI: 10.1002/lt.24729] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
76 Qin G, Zhao C, Zhang L, Liu H, Quan Y, Chai L, Wu S, Wang X, Chen T. Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells. Apoptosis 2015;20:1072-86. [PMID: 25935454 DOI: 10.1007/s10495-015-1132-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
77 Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol 2016;22:7289-300. [PMID: 27621575 DOI: 10.3748/wjg.v22.i32.7289] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 52] [Article Influence: 16.3] [Reference Citation Analysis]
78 Pasciak AS, Abiola G, Liddell RP, Crookston N, Besharati S, Donahue D, Thompson RE, Frey E, Anders RA, Dreher MR, Weiss CR. The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. Eur J Nucl Med Mol Imaging 2020;47:816-27. [PMID: 31741021 DOI: 10.1007/s00259-019-04588-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
79 Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, Herfarth K, Guckenberger M. Stereotactic body radiotherapy for liver tumors: Principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 2014;190:872-81. [DOI: 10.1007/s00066-014-0714-1] [Cited by in Crossref: 66] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
80 Pottier A, Borghi E, Levy L. The future of nanosized radiation enhancers. Br J Radiol 2015;88:20150171. [PMID: 26248871 DOI: 10.1259/bjr.20150171] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
81 Park S, Yoon WS, Jang MH, Rim CH. Clinical efficacy of external beam radiotherapy complementing incomplete transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Biol 2020;96:1541-9. [PMID: 32990486 DOI: 10.1080/09553002.2020.1830316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 11.8] [Reference Citation Analysis]
83 Yu JI, Park HC, Lim DH, Paik SW. Do Biliary Complications after Hypofractionated Radiation Therapy in Hepatocellular Carcinoma Matter? Cancer Res Treat. 2016;48:574-582. [PMID: 26194367 DOI: 10.4143/crt.2015.076] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
84 Choi C, Son A, Lee GH, Shin SW, Park S, Ahn SH, Chung Y, Yu JI, Park HC. Targeting DNA-dependent protein kinase sensitizes hepatocellular carcinoma cells to proton beam irradiation through apoptosis induction. PLoS One 2019;14:e0218049. [PMID: 31194786 DOI: 10.1371/journal.pone.0218049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
85 Huang Y, Lu Y, Lu S. Sequential bilateral PVTT successfully controlled by radiotherapy and sorafenib, respectively. Kaohsiung J Med Sci 2019;35:63-4. [DOI: 10.1016/j.kjms.2018.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Cui X, Zhang A, Liu J, Wu K, Chen Z, Wang Q. Down-regulation of MAP2K1 by miR-539 inhibits hepatocarcinoma progression. Biochemical and Biophysical Research Communications 2018;504:784-91. [DOI: 10.1016/j.bbrc.2018.08.076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]